GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more
Location: 1525 O’Brien Drive, Menlo Park, CA, 94025, United States | Website: https://grail.com | Industry: Diagnostics & Research | Sector: Healthcare
Market Cap
2.224B
52 Wk Range
$12.57 - $73.74
Previous Close
$65.54
Open
$66.47
Volume
1,265,170
Day Range
$60.02 - $66.53
Enterprise Value
1.793B
Cash
602.8M
Avg Qtr Burn
-92.51M
Insider Ownership
13.79%
Institutional Own.
68.56%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|